Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sodium valproate, platelet dysfunction, and bleeding.

P Loiseau

    Epilepsia
    |April 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Sodium valproate (VPA), an antiepileptic, may cause bleeding issues like thrombocytopenia. Doctors should monitor patients, especially those undergoing surgery, and consider limiting VPA dosages to below 40 mg/kg/day.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Influence of Collisional Effects on Ion-Acoustic Wave Properties in Non-Maxwellian Laser-Driven Plasmas.

    Physical review letters·2025
    Same author

    Experimental Evidence of Stimulated Raman Rescattering in Laser-Plasma Interaction.

    Physical review letters·2025
    Same author

    Statistical model of the stimulated forward Brillouin scattering driven by a randomized laser beam in plasma.

    Physical review. E·2025
    Same author

    Nonlinear kinetic estimate of Raman reflectivity in a hohlraum plasma with a radiation hydrodynamics code.

    Physical review. E·2024
    Same author

    Dynamics of Nanosecond Laser Pulse Propagation and of Associated Instabilities in a Magnetized Underdense Plasma.

    Physical review letters·2023
    Same author

    Influence of a random phase plate on the growth of the backward stimulated Brillouin scatter.

    Physical review. E·2023
    Same journal

    Semiology of functional/dissociative seizures in idiopathic generalized epilepsy: An inpatient video-electroencephalographic study.

    Epilepsia·2026
    Same journal

    Perineuronal net abnormalities in epileptic human tissue.

    Epilepsia·2026
    Same journal

    Cortical stimulation reveals effective disconnection of the epileptogenic network at seizure onset.

    Epilepsia·2026
    Same journal

    Anterior cingulate cortex neuron subtypes differentially regulate seizures.

    Epilepsia·2026
    Same journal

    Ultrafast oscillations in the human brain and their functional significance.

    Epilepsia·2026
    Same journal

    Magnetoencephalographic source imaging improves localization of the epileptogenic zone in multimodal imaging evaluation.

    Epilepsia·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Hematology
    • Clinical Medicine

    Background:

    • Sodium valproate (VPA) is an antiepileptic drug with known hematological side effects.
    • Thrombocytopenia and platelet dysfunction are potential adverse effects of VPA.
    • These side effects may increase bleeding risk, particularly in surgical patients.

    Purpose of the Study:

    • To review the clinical significance of VPA-induced thrombocytopenia and platelet dysfunction.
    • To assess the utility of thromboelastography in screening for VPA-related hematological abnormalities.
    • To provide guidance on VPA dosage to minimize adverse effects.

    Main Methods:

    • Literature review on VPA's hematological effects.
    • Analysis of clinical data regarding VPA-induced bleeding.

    Related Experiment Videos

  • Evaluation of thromboelastography as a diagnostic tool.

    • Main Results:

    • VPA can cause thrombocytopenia or platelet dysfunction, potentially leading to hemorrhage.
    • These side effects are considered infrequent but clinically relevant, especially perioperatively.
    • Thromboelastography is identified as a reliable screening method for these abnormalities.

    Conclusions:

    • VPA-induced hematological abnormalities are often dose-dependent.
    • Dosages of VPA exceeding 40 mg/kg/day are not recommended to mitigate risks.
    • Careful patient monitoring and appropriate VPA dosing are crucial for surgical patients.